Voya Investment Management LLC decreased its position in Incyte Co. (NASDAQ:INCY) by 5.9% during the 2nd quarter, Holdings Channel reports. The firm owned 99,973 shares of the biopharmaceutical company’s stock after selling 6,224 shares during the quarter. Voya Investment Management LLC’s holdings in Incyte were worth $6,698,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. grew its holdings in Incyte by 1.5% during the 2nd quarter. BlackRock Inc. now owns 14,482,092 shares of the biopharmaceutical company’s stock worth $970,300,000 after acquiring an additional 209,498 shares during the last quarter. Manning & Napier Group LLC grew its holdings in Incyte by 128.5% during the 2nd quarter. Manning & Napier Group LLC now owns 4,284,594 shares of the biopharmaceutical company’s stock worth $287,067,000 after acquiring an additional 2,409,374 shares during the last quarter. BB Biotech AG grew its holdings in Incyte by 1.6% during the 2nd quarter. BB Biotech AG now owns 3,758,322 shares of the biopharmaceutical company’s stock worth $251,808,000 after acquiring an additional 60,000 shares during the last quarter. Carmignac Gestion grew its holdings in Incyte by 12.2% during the 1st quarter. Carmignac Gestion now owns 1,087,414 shares of the biopharmaceutical company’s stock worth $90,614,000 after acquiring an additional 118,299 shares during the last quarter. Finally, Frontier Capital Management Co. LLC grew its holdings in Incyte by 146.5% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 996,359 shares of the biopharmaceutical company’s stock worth $66,756,000 after acquiring an additional 592,132 shares during the last quarter. 91.50% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have commented on the stock. BidaskClub raised shares of Incyte from a “sell” rating to a “hold” rating in a report on Saturday, June 23rd. Oppenheimer set a $70.00 price objective on shares of Incyte and gave the stock a “hold” rating in a report on Thursday, September 13th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $88.00 target price on shares of Incyte in a research note on Sunday, June 24th. Guggenheim assumed coverage on shares of Incyte in a research note on Monday, September 17th. They issued a “neutral” rating on the stock. Finally, Leerink Swann assumed coverage on shares of Incyte in a research note on Monday. They issued a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and sixteen have given a buy rating to the stock. Incyte has an average rating of “Buy” and an average price target of $100.51.

Shares of NASDAQ INCY opened at $66.48 on Tuesday. The stock has a market capitalization of $14.16 billion, a PE ratio of 475.64 and a beta of 1.14. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.32 and a current ratio of 4.34. Incyte Co. has a 1 year low of $60.22 and a 1 year high of $118.32.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.22. The business had revenue of $521.50 million for the quarter, compared to the consensus estimate of $510.70 million. Incyte had a negative net margin of 5.92% and a positive return on equity of 1.74%. Incyte’s revenue for the quarter was up 59.8% on a year-over-year basis. During the same period last year, the company posted ($0.06) EPS. analysts expect that Incyte Co. will post 0.43 EPS for the current year.

In related news, EVP Vijay K. Iyengar sold 606 shares of the stock in a transaction that occurred on Monday, July 9th. The shares were sold at an average price of $71.34, for a total value of $43,232.04. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paula J. Swain sold 10,000 shares of the stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $70.00, for a total transaction of $700,000.00. Following the completion of the sale, the executive vice president now owns 42,324 shares in the company, valued at $2,962,680. The disclosure for this sale can be found here. Insiders sold a total of 20,606 shares of company stock worth $1,475,332 over the last quarter. 17.20% of the stock is currently owned by corporate insiders.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Featured Story: Price to Earnings Ratio (PE), For Valuing Stocks

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.